Premium
OUTCOMES AFTER FIRST‐LINE IMMUNOCHEMOTHERAPY FOR PRIMARY MEDIASTINAL B CELL LYMPHOMA PATIENTS: A LYSA STUDY
Author(s) -
Camus V.,
Rossi C.,
Sesques P.,
Lequesne J.,
Tonnelet D.,
Haioun C.,
Durot E.,
Willaume A.,
Gauthier M.,
MolesMoreau MarieP.,
Antier C.,
Lazarovici J.,
Monjanel H.,
Bernard S.,
Tardy M.,
Besson C.,
Lebras L.,
Choquet S.,
Le Du K.,
Bonnet C.,
Bailly S.,
Damaj G.L.,
Laribi K.,
Maisonneuve H.,
Houot R.,
Chauchet A.,
Jardin F.,
TraverseGlehen A.,
Decazes P.,
Becker S.,
BerrioloRiedinger A.,
Tilly H.
Publication year - 2021
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.50_2879
Subject(s) - medicine , rituximab , clinical endpoint , chop , lymphoma , progression free survival , oncology , chemotherapy , clinical trial